Characterization of a WiT49 cell line derived orthotopic model of Wilms tumor

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 316-318

  Li, Mei Hong ^a,b   Yamase, Harold ^a   Ferrer, Fernando ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Division of Pediatric Infectious Diseases   (United States)

Author keywords

Orthotopic model; Wilms tumor; WiT49

Indexed keywords

EOSIN; HEMATOXYLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KIDNEY TUMOR; MALE; METASTASIS; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; STAINING; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, NUDE; WILMS TUMOR;

EID: 74849137842     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22205     Document Type: Article

References (18)

1. Alami J,Williams BR, Yeger H. Derivation and characterization of aWilms' tumour cell line,WiT 49. Int J Cancer 2003;107:365-374.
2. Paulino AC, Wen BC, Brown CK, et al. Late effects in children treated with radiation therapy forWilms' tumor. Int J Radiat Oncol Biol Phys 2000;46:1239-1246.
3. Egeler RM, Wolff JE, Anderson RA, et al. Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Semin Urol Oncol 1999;17:55-61.
4. Othman F, Guo CY, Webber C, et al. Osteopenia in survivors of Wilms tumor. Int J Oncol 2002;20:827-833.
5. Green DM, Peabody EM, Nan B, et al. Pregnancy outcome after treatment for Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 2002;20:2506-2513.
6. Trebo MM, Mann G, Dworzak M, et al. Wilms tumor and cardiomyopathy. Med Pediatr Oncol 2003;41:574.
7. Cespedes MV, Casanova I, Parreno M, et al. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006;8:318-329.
8. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59:221-226.
9. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-7790.
10. Li TK, Houghton PJ, Desai SD, et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 2003;63:8400-8407.
11. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
12. Soffer SZ, Moore JT, Kim E, et al. Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001;36:1177-1181.
13. Frischer JS, Huang J, Serur A, et al. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol 2004;25:549-553.
14. Smith MA, Morton CL, Phelps D, et al. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 2008;50:703-706.
15. Garvin AJ, Re GG, Tarnowski BI, et al. The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol 1993;142:375-380.
16. Weissman BE, Saxon PJ, Pasquale SR, et al. Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science (New York, NY) 1987;236:175-180.
17. Dowdy SF, Fasching CL, Araujo D, et al. Suppression of tumorigenicity in Wilms tumor by the p15.5-p14 region of chromosome 11. Science (New York, NY) 1991;254:293-295.
18. Wheeler TT, Xiao JP, Dowdy SF, et al. Suppression of tumorigenicity of aWilms' tumor cell line is associated with a decrease in synthesis of two proteins. Oncogene 1991;6:1903-1907.